IMPORTANCE-Bilateral mastectomy is increasingly used to treat unilateral breast cancer. Because it may have medical and psychosocial complications, a better understanding of its use and outcomes is essential to optimizing cancer care.
minimize selection bias, we designed a population-based study of the use and outcomes of bilateral mastectomy compared with other surgical treatments, using the California Cancer Registry (CCR, part of the National Cancer Institute [NCI] Surveillance, Epidemiology and End Results [SEER] program), which comprises about 99% of all breast cancer cases statewide.
Methods

Case Ascertainment and Data Collection
The study population consisted of all female California residents newly diagnosed with a first primary breast cancer (International Classification of Diseases-Oncology, 3rd edition, morphology codes C50.0-50.9), of American Joint Commission on Cancer stages 0-III, from January 1, 1998, through December 31, 2011. Approval for human subjects research was obtained from the Cancer Prevention Institute of California institutional review board. We obtained CCR data routinely abstracted from medical records on age at diagnosis, race/ ethnicity (from patients' medical records and registry categorization; assessed because prior research indicates that the use of and survival after surgical procedures vary by race/ ethnicity, and because we aimed to evaluate these associations in a population-based context), marital status, stage, tumor grade, tumor size, histology, lymph node involvement, metastasis, and biomarkers. 14 Tumors with histologic morphology codes 8500-8508 and 8521-8523 were coded as ductal and those with codes 8520 and 8524-8525 as lobular. We also obtained CCR information on initial treatment (surgery, chemotherapy, and radiation therapy), primary health insurance, census block group of residence at diagnosis, and vital status (determined by CCR through hospital follow-up and database linkages, including the Social Security Administration) as of December 31, 2010 , and, for the deceased, the underlying cause of death.
Tumor Biomarker Information
Estrogen-receptor and progesterone-receptor status were each categorized as positive (≥5% nuclear staining), negative, borderline, not tested, not recorded, or unknown. Tumors were considered estrogen receptor-/progesterone receptor-positive if they were estrogen receptor-positive, progester-one receptor-positive, or both, and as estrogen receptor-/ progesterone receptor-negative if both were negative. Given that CCR did not systematically collect v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2 (ERBB2, also known as HER-2/neu, unigene cluster number Hs.446352) testing results before 2006, ERBB2 data are not included.
Neighborhood Socioeconomic Information
For each case, we assigned a previously developed measure of neighborhood socioeconomic status (SES). For cases diagnosed in 1998-2005, we used a measure of neighborhood-level SES quintiles based on distribution across California, incorporating block group-level data from the 2000 Census on income, education, housing costs, and occupation. 15 For cases diagnosed in 2006-2010, we used data from the American Community Survey of the US Census to derive a similar index.
Hospital-Level Information
The CCR records the facility reporting each case. Using the aforementioned index, we determined the SES distribution of all cases for each facility and identified facilities that were NCI-designated cancer centers.
Statistical Analysis
We used polytomous logistic regression to model surgery use. Survival time was measured in days from diagnosis to death. Women who died from other causes were censored at time of death for the analysis of breast cancer-specific mortality. Women alive at the time of last follow-up or December 31, 2010, were censored then. We used Cox proportional hazards to model the association of various factors with overall and breast cancer-specific mortality. The proportional hazards assumption was confirmed by testing the correlation of Schoenfeld residuals with time. For both models (surgery use and mortality), covariates included age, race/ethnicity, tumor size, grade, histology, nodal and estrogen receptor/progesterone receptor status, receipt of adjuvant chemotherapy and radiation, neighbor hood SES quintile, marital and insurance status, the SES composition of patients at the reporting hospital, care at an NCI-designated cancer center, and diagnosis year. Stage was included as a stratifying variable in the Cox regression, allowing baseline hazards to vary by stage. Multicol-linearity in the models was assessed using the variance inflation factor. We did not test for a priori interactions but did conduct stratified analyses by age and stage. Missing data were coded as unknown and retained as a separate category for analyses.
We used SAS version 9.3 for all analyses except those of surgical use trends, for which we used Joinpoint (Joinpoint Regression Program version 4.0.4 [Statistical Research and Applications Branch, NCI]). This program uses Monte Carlo Permutation tests to model data and identify up to 3 points ("joinpoints") at which there was a statistically significant change in linear trend. 16 Results of joinpoint analysis were used to inform grouping of diagnosis years in logistic regression analysis.
Propensity score analyses defined surgery type as the patient attribute for which scores were calculated. 17 We used generalized boosting models, a nonparametric machine-learning classifier, in the R package twang, setting the search limit to 15 000 trees. 18 All independent variables in Table 1 and Table 2 were used to calculate per-patient scores, except 3 variables highly correlated with others (radiation therapy with surgery type; chemotherapy and adjuvant treatment with administration of chemotherapy before or after the surgical procedure).
We used graphical analysis to assess the postbalance maximum standardized effect difference for each variable 17 and calculated weights for the average treatment effect (average outcome for the whole population after one surgery vs another); and average treatment effect for those treated (average out come for those treated after one surgery vs another). The svykm and svylogrank functions from the survey package 19 were used to calculate weighted Kaplan-Meier curves and P values; the svycoxph function was used for stratified by stage. Weighted CIs for mortality rates were calculated by the survfit function in the R survival package.
Results
Patient Characteristics
A total of 291 117 stages 0-III breast cancer cases were diagnosed and reported to CCR from January 1, 1998, through December 31, 2011. Cases were excluded if missing essential data for categorization or if ineligible for breast-conserving surgery with radiation according to practice guide lines, 20 as follows: diagnosed by death certificate or autopsy only (n = 33); tumor larger than 5 cm or unknown, microscopic or diffuse tumor, Paget disease of breast or mammographic diagnosis only, or inflammatory carcinoma (n = 41 853); no pathology report confirmation (n = 283); unknown lymph node involvement (n = 1771); surgery other than bilateral mastectomy, breast-conserving surgery with radiation, or unilateral mastectomy (n = 52 343); and diagnosis of bilateral tumors or a second primary breast tumor within 60 days (n = 5100), resulting in 189 734 women included in analyses of surgery use. Mortality analyses excluded women diagnosed after 2010 because of incomplete mortality data for 2011 (n = 14 331), those having zero or invalid survival time (n = 11), and those having unknown cause of death (n = 475). Mortality analyses included 174 917 women; median follow-up time was 89.1 months (inter quartile range, 54.8-129.9 months).
The proportions of all patients who underwent each surgery were 6.2% (95% CI, 6.1%-6.3%) for bilateral mastectomy, 55.0% (95%, 54.8%-55.3%) for breast-conserving surgery with radiation; and 38.8% (95% CI, 38.6%-39.0%) for unilateral mastectomy (Table 1 and eTable in the Supplement). Among all patients, the rate of bilateral mastectomy increased from 2.0% (95% CI, 1.7%-2.2%) in 1998 to 12.3% (95% CI, 11.8%-12.9%) in 2011, an annual increase of 14.3% (95% CI, 13.1%-15.5%)( Table 2 and eTable). The increase in bilateral mastectomy rate was greatest among women younger than 40 years: the rate increased from 3.6% (95% CI, 2.3%-5.0%) in 1998 to 33.0% (95% CI, 29.8%-36.5%) in 2011, increasing by 17.6% (95% CI, 14.9%-20.4%) annually. Use of unilateral mastectomy declined in all age groups ( Figure 1 ).
Multiple Regression Analysis of Characteristics Associated With Surgical Type
Factors associated with having undergone bilateral mastectomy (vs breast-conserving surgery with radiation) included age younger than 50 years, non-Hispanic white race/ ethnicity, larger tumor size, nodal involvement, lobular histology, higher grade or estrogen receptor-/progesterone receptor-negative status, care at a hospital predominantly serving patients with lower SES or at an NCI-designated cancer center, having higher neighborhood SES, and recent diagnosis. Factors inversely associated with having undergone bilateral mastectomy (vs breast-conserving surgery with radiation) included age 65 years or older, minority race/ethnicity, receipt of adjuvant therapy, married status, and insurance type other than private (Table 3) .
Characteristics associated with having undergone unilateral mastectomy (vs breastconserving surgery plus radiation) included diagnosis at age other than 50 to 64 years, Asian, Hispanic, and American Indian race/ethnicity (with notable associations for Filipina and Hispanic women vs non-Hispanic white women), larger tumor size, nodal involvement, lobular histology, higher grade, estrogen receptor-/progesterone receptor-negative status, married status, public/Medicaid insurance, or care at a hospital predominantly serving patients of lower SES (Table 3) . Factors inversely associated with having unilateral mastectomy (vs breast-conserving surgery with radiation) included black race, receipt of adjuvant therapy, care at an NCI-designated cancer center, higher neighborhood SES, and recent diagnosis.
Multiple Regression Analysis of Mortality After Surgery
Compared with breast-conserving surgery with radiation, bilateral mastectomy was not associated with a mortality difference (hazard ratio [HR], 1.02 [95% CI, 0.94-1.11]), whereas unilateral mastectomy was associated with higher mortality (HR, 1.35[95% CI, 1.32-1.39]) ( Table 4 ). Other factors associated with overall mortality included age 65 years or older or younger than 40 years, black race, larger tumor size, nodal involvement, higher grade, estrogen receptor-/progesterone receptor-negative status, lower neighborhood SES, unmarried status, having Medicare or public/Medicaid insurance, and receiving care at a hospital predominantly serving patients of lower SES. Higher mortality was associated with unilateral mastectomy in all age groups. Similar mortality between bilateral mastectomy and breast-conserving surgery with radiation was observed in all age groups except women 65 years or older, whose survival was slightly better after breast-conserving surgery with radiation. Findings were similar for breast cancer-specific mortality ( Table 5 ). Compared with unilateral mastectomy, bilateral mastectomy was associated with lower overall mortality (HR, 0.75 [95% CI, 0.70-0.82]) and breast cancer-specific mortality (HR, 0.85 [95% CI, 0.76-0.94]). Figure 2A shows estimated mortality among all patients if surgical procedure were randomly assigned (analysis of average treatment effect). The estimated 10-year mortality rates were 18.8% (95% CI, 18.6%-19.0%) for bilateral mastectomy, 16.8% (95% CI, 16.6%-17.1%) for breast-conserving surgery with radiation, and 20.1% (95%CI, 19.9%-20.4%) for unilateral mastectomy. Figure 2B -D shows estimated mortality from another surgical procedure among patients who had a specific surgical procedure (analysis of average treatment effect for those treated). For patients receiving breast-conserving surgery with radiation, bilateral mastectomy would have resulted in marginally higher mortality, on average, and unilateral mastectomy in higher mortality. For patients receiving unilateral mastectomy, bilateral mastectomy would have resulted in unchanged mortality and breastconserving surgery with radiation in lower mortality. For patients receiving bilateral mastectomy, breast-conserving surgery with radiation would have resulted in unchanged mortality and unilateral mastectomy in higher mortality. Proportional hazards regression models showed similar results ( Table 6 ). Kurian 
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Discussion
This observational study comprising 189 734 women with unilateral early-stage breast cancer compared 3 surgical treatments and found a substantial increase in the rate of bilateral mastectomy throughout California from 1998 through 2011. To our knowledge, this is the first side-by-side comparison of all 3 common surgical treatments for early-stage breast cancer. Previous SEER studies have compared 2 treatments at a time: some reported a survival advantage with bilateral vs unilateral mastectomy 21, 22 and others reported improved survival after breast-conserving surgery with radiation compared with unilateral mastectomy. 23, 24 By comparing all 3 surgical options for a patient with early-stage breast cancer, we found no mortality benefit associated with bilateral mastectomy compared with breast-conserving surgery, and higher mortality associated uniquely with unilateral mastectomy.
For the surgical treatment of early-stage breast cancer, available randomized trial data are limited to those showing no survival difference between unilateral mastectomy and breastconserving surgery. 1, 2 There is no randomized trial evidence to inform whether bilateral mastectomy improves survival, and it is unlikely that such a trial will ever be performed. Thus, conclusions about surgical treatments must rely on observational studies that compare the effectiveness of different procedures in practice 21, 22, 25, 26 ; however, a recent metaanalysis judged the existing data inadequate to enable conclusions about the effect of bilateral mastectomy on survival. 27 Patient selection attributable to unmeasured factors probably explains much of the higher mortality that we observed with unilateral mastectomy relative to the other 2 surgical procedures. In prior SEER-based studies, both we 24 and Agarwal et al 23 reported worse survival associated with unilateral mastectomy vs breastconserving surgery with radiation, results that persisted after propensity analysis. We agree with previous suggestions that patients with tumor features suggesting poor prognosis, such as lymphovascular invasion or extranodal extension, which SEER does not record and for which we cannot control, are more likely to undergo unilateral mastectomy than breast conservation and also to experience worse survival. 23, 24 The current study offers another potential explanation, namely confounding related to sociodemographic differences between women who underwent bilateral mastectomy and women who underwent unilateral mastectomy.
Women who underwent bilateral mastectomy were more likely to be non-Hispanic white and privately insured, to live in high SES neighborhoods, and to be treated in NCI-designated cancer centers. By contrast, women who underwent unilateral mastectomy were more likely to be Asian, Hispanic, or non-Hispanic American Indian/other/unknown; to have public/ Medicaid insurance, and to be treated in hospitals serving patients of lower SES; they were less likely to live in high SES neighborhoods or to be treated in NCI-designated cancer centers. Cancer registry data lack details about comorbidities and specific regimens of endocrine, radiation, and chemotherapy. However, prior studies enriched for clinical data, including our own within the Kaiser Permanente Northern California health care system, reported treatment-limiting comorbidities (for example, diabetes and myocardial infarction) and reduced treatment intensity among the same racial/ethnicminority, low SES patients who most frequently under went unilateral mastectomy in our current study. [28] [29] [30] In addition to signifying unmeasured poor prognostic factors, 21, 22 unilateral mastectomy might correlate with subtle disparities in effective access (for example, diabetic neuropathy that limits chemotherapy dosing; lack of transportation to the postsurgical radiation treatments required for breast conservation) that we could not identify using registry data and that may mediate higher mortality. By contrast, patterns of bilateral mastectomy use suggest that affluent non-Hispanic white women, women of high SES, or both seek more aggressive preventive care, consistent with reported associations between greater use of expensive diagnostic tests (such as breast MRI and genetic testing) and bilateral mastectomy within this patient subgroup. 4, 31 The increase in bilateral mastectomy use despite the absence of supporting evidence has puzzled clinicians and health policy makers. Proposed explanations include the increasing use of highly sensitive breast magnetic resonance imaging, with increases in anxietyproducing recall and biopsy rates that may drive patients to undergo preventive surgery, 6, 31, 32 and the dissemination of genetic testing, which facilitates identification of high-risk patients who benefit from bilateral mastectomy. 7, 8, 33 Although fear of cancer recurrence may prompt the decision for bilateral mastectomy, such fear usually exceeds the estimated risk. 34, 35 Other studies found recurrence fears less influential than aesthetic considerations, notably those that arise with new reconstruction approaches that achieve cosmetic symmetry through bilateral tissue flap placement. 6, 36 Because cosmesis may be inferior if both breasts are not reconstructed simultaneously, these new approaches encourage use of immediate bilateral mastectomy. We found that bilateral mastectomy use over time increased most among patients younger than 40 years at diagnosis, which may be attributable to their relatively high probability of carrying genetic mutations (an evidencebased indication for bilateral mastectomy) 37 or to the greater likelihood that they have young children and may therefore seek maximal intervention in hope of extending their lives (an emotional rather than evidence-based decision). 34, 35, 38 Although some studies reported patient satisfaction after bilateral mastectomy, 39 others observed deleterious effects on body image, sexual function, and quality of life 12 ; moreover, repeat operations and complications (including flap failure, necrosis, and infection) are substantially more common with bilateral mastectomy than with other surgical procedures. 10, 11 In a time of increasing concern about overtreatment, 40 the risk-benefit ratio of bilateral mastectomy warrants careful consideration and raises the larger question of how physicians and society should respond to a patient's preference for a morbid, costly intervention of dubious effectiveness.
Our study used a population-based statewide data set, multiple regression analysis, and propensity scores. However, given its observational design, it cannot prove causation and may be subject to selection bias and uncontrolled confounding. As discussed above, unmeasured patient selection factors related to cancer prognosis and access to care may explain the higher mortality observed with unilateral mastectomy. Other limitations include the lack of SEER data on diagnostic testing (eg, magnetic resonance imaging, genetic testing for BRCA1/2 and other inherited mutations, tumor analysis for ERBB2 amplification, and broader genomic profiling), details of systemic treatments, family cancer history, and comorbidities. Additional information gaps include patient preferences and physician recommendations, which influence surgical decisions. 38 Future research with more comprehensive data sets that integrate detailed clinical, treatment, and patient-reported information will be essential to advance understanding of breast surgery use and to enhance the quality of cancer care.
Conclusions
Among all women diagnosed with early-stage breast cancer in California, the percentage undergoing bilateral mastectomy increased substantially between 1998 and 2011, despite a lack of evidence supporting this approach. Bilateral mastectomy was not associated with lower mortality than breast-conserving surgery plus radiation, but unilateral mastectomy was associated with higher mortality than the other options. These results may inform decisionmaking about the surgical treatment of breast cancer.
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